Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Sulforaphane, a compound found in cruciferous vegetables such as broccoli, has attracted scientific interest for its potential role in supporting or treating diabetic retinopathy, a common complication of diabetes that affects the eyes. The primary rationale for its use is based on its strong antioxidant and anti-inflammatory properties. Preclinical studies, particularly in cell culture and animal models, have demonstrated that sulforaphane can reduce oxidative stress and inflammation in retinal cells exposed to high glucose conditions, which are central to the pathogenesis of diabetic retinopathy. These studies suggest that sulforaphane helps protect the retinal vasculature by activating the Nrf2 pathway, which increases the expression of protective antioxidant enzymes and decreases the expression of pro-inflammatory molecules. However, the evidence is still at an early stage. As of mid-2024, there are no large-scale human clinical trials directly assessing sulforaphane supplementation in patients with diabetic retinopathy. Most of the available data are from laboratory or animal studies. While these findings are promising and provide a mechanistic rationale for potential benefit, the lack of human clinical evidence means that sulforaphane cannot yet be recommended as a proven therapeutic agent for diabetic retinopathy. More research, particularly well-designed human clinical trials, is needed to confirm its efficacy and safety in this context.

More about Sulforophane
More about Diabetic Retinopathy

Other ingredients used for Diabetic Retinopathy

Other health conditions supported by Sulforophane

Products containing Sulforophane